Experienced in Deep Vein Thrombosis

Dr. Micah M. Burch

Oncology | Hematology
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
Offers Telehealth
20 Years of Experience

Experienced in Deep Vein Thrombosis
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Micah Burch is a Hematologist and an Oncologist in Dallas, Texas. Dr. Burch has been practicing medicine for over 20 years and is rated as an Experienced provider by MediFind in the treatment of Deep Vein Thrombosis. His top areas of expertise are Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Acute Myeloid Leukemia (AML), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Oklahoma Health Science Center, 2006.0
Residency
Internal Medicine, Scott and White Graduate Medical Education
Specialties
Oncology
Hematology
Licenses
Internal Medicine in TX
Fellowships
Oncology, Baylor University Medical Center
Hospital Affiliations
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246
Call: 972-449-0540

Additional Areas of Focus

Dr. Burch has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 1
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
View 5 Less Clinical Trials

9 Total Publications

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Journal: Blood advances
Published: June 12, 2023
View All 9 Publications
Similar Doctors
Advanced in Deep Vein Thrombosis
Dr. Swapna Goday
Hematology | Oncology | Internal Medicine
Advanced in Deep Vein Thrombosis
Dr. Swapna Goday
Hematology | Oncology | Internal Medicine

The Center For Cancer & Blood Disorders - Southlake

630 E Hwy 114, 
Southlake, TX 
 (24.5 miles away)
817-759-9000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Swapna Goday is a Hematologist and an Oncologist in Southlake, Texas. Dr. Goday is rated as an Advanced provider by MediFind in the treatment of Deep Vein Thrombosis. Her top areas of expertise are Deep Vein Thrombosis, Pulmonary Embolism, Thrombocytopenia, and Anemia.

Shadan Mansoor
Advanced in Deep Vein Thrombosis
Dr. Shadan Mansoor
Oncology | Hematology
Advanced in Deep Vein Thrombosis
Dr. Shadan Mansoor
Oncology | Hematology

The Center For Cancer & Blood Disorders - Burleson

11805 S Fwy, Ste 201, 
Burleson, TX 
 (34.3 miles away)
817-759-7000
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Shadan Mansoor is a Hematologist and an Oncologist in Burleson, Texas. Dr. Mansoor is rated as a Distinguished provider by MediFind in the treatment of Deep Vein Thrombosis. Her top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, and Familial Colorectal Cancer.

Advanced in Deep Vein Thrombosis
Dr. Ruben A. Saez
Hematology | Oncology
Advanced in Deep Vein Thrombosis
Dr. Ruben A. Saez
Hematology | Oncology

Texas Oncology - West Plano

6957 W Plano Pkwy, Ste 2000A, 
Plano, TX 
 (17.4 miles away)
214-483-6933
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Ruben Saez is a Hematologist and an Oncologist in Plano, Texas. Dr. Saez is rated as a Distinguished provider by MediFind in the treatment of Deep Vein Thrombosis. His top areas of expertise are Non-Hodgkin Lymphoma, Childhood Iron Deficiency Anemia, Paget Disease of the Breast, Bone Marrow Aspiration, and Gastrostomy.

VIEW MORE DEEP VEIN THROMBOSIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burch's expertise for a condition
ConditionClose
    • Distinguished
    • Large-Cell Immunoblastic Lymphoma
      Dr. Burch is
      Distinguished
      . Learn about Large-Cell Immunoblastic Lymphoma.
      See more Large-Cell Immunoblastic Lymphoma experts
    • Multiple Myeloma
      Dr. Burch is
      Distinguished
      . Learn about Multiple Myeloma.
      See more Multiple Myeloma experts
    • Advanced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Burch is
      Advanced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Burch is
      Advanced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Burch is
      Advanced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Bone Marrow Aspiration
      Dr. Burch is
      Advanced
      . Learn about Bone Marrow Aspiration.
      See more Bone Marrow Aspiration experts
    • Childhood Acute Myeloid Leukemia
      Dr. Burch is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Burch is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    View All 11 Advanced Conditions
    • Experienced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Burch is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myelomonocytic Leukemia
      Dr. Burch is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Adult Soft Tissue Sarcoma
      Dr. Burch is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Burch is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anemia
      Dr. Burch is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    • Angiosarcoma
      Dr. Burch is
      Experienced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.